Manuel Vaz-Da-Silva

Manuel Vaz-Da-Silva

Auto-generated profile, based on publicly available information

Manuel Vaz-Da-Silva

Bial

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2009 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
LALuis Almeida
Luis Almeida
MVManuel Vaz‐Da‐Silva
Manuel Vaz‐Da‐Silva
AFAmílcar Falcão
Amílcar Falcão
ESEva Soares
Eva Soares
RCRaquel Costa
Raquel Costa
PSPatrício Soares‐Da‐Silva
Patrício Soares‐Da‐Silva

1 December 2009 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
TNTeresa Nunes
Teresa Nunes
LALuis Almeida
Luis Almeida
JRJosé‐Francisco Rocha
José‐Francisco Rocha
AFAmílcar Falcão
Amílcar Falcão
CFCarlos Fernandes‐Lopes
Carlos Fernandes‐Lopes
PSPatrício Soares‐Da‐Silva
Patrício Soares‐Da‐Silva

1 November 2008 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
MVM. Vaz-Da-Silva
M. Vaz-Da-Silva
ALA.I. Loureiro
A.I. Loureiro
AFAmílcar Falcão
Amílcar Falcão
TNT. Nunes
T. Nunes
JRJ.-F. Rocha
J.-F. Rocha
PSP. Soares-Da-Silva
P. Soares-Da-Silva
It has been postulated that trans-resveratrol may act as an antioxidant, cardioprotective, neuroprotective and cancer chemopreventive agent. The objective of this study was to investigate the effect of food on the bioavailability of trans-resveratrol following oral administration. Single-centre, open-label, randomized, 2-way crossover study on 24 healthy subjects. The study consisted of two consecutive treatment periods separated by a washout of 7 days or more. On each of the study periods subjects were administered a single-dose of 400 mg of trans-resveratrol following either a standard high fat content meal or 8 hs of fasting. There was a large interindividual variability in the trans-resveratrol pharmacokinetic parameters. Mean +/- SD maximum plasma concentration (Cmax) was 42.2 +/- 36.6 ng/ml in fed and 47.3 +/- 30.0 ng/ml in fasting conditions. Median time to Cmax (tmax) was 2.0 h in fed and 0.5 h in fasting (p < 0.0001). The fed/fasting geometric mean ratio (GMR) and 90% confidence interval (90% CI) were 79.4 and 53.8, 117.0% for Cmax, and 106.0 and 86.8, 128.0% for the area under the plasma concentration-time curve (AUC0- yen). The 90% CI for the GMR of AUC0- yen and Cmax fall outside the usual bioequivalence acceptance range of 80, 125%, but that of AUC0- yen was close to the bioequivalence standard. The rate of absorption of trans-resveratrol following an oral 400 mg single-dose was significantly delayed by the presence of food, as reflected by Cmax and tmax. However, the extent of absorption, as reflected by AUC- yen, was not affected in a relevant way.

20 September 2007 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
LALuis Almeida
Luis Almeida
BABenedita Azevedo
Benedita Azevedo
TNTeresa Nunes
Teresa Nunes
MVManuel Vaz-Da-Silva
Manuel Vaz-Da-Silva
PSPatrício Soares-Da-Silva
Patrício Soares-Da-Silva

12 June 2013 in Epilepsia
Verified
Journal Article
Closed access
PDF file
CEChristian Elger
Christian Elger
MBMeir Bialer
Meir Bialer
AFAmílcar Falcão
Amílcar Falcão
MVManuel Vaz‐Da‐Silva
Manuel Vaz‐Da‐Silva
TNTeresa Nunes
Teresa Nunes
PSPatrício Soares‐Da‐Silva
Patrício Soares‐Da‐Silva

1 January 2005 in Drugs in R&D
Verified
Journal Article
Closed access
PDF file
JMJoana Maia
Joana Maia
MVManuel Vaz-Da-Silva
Manuel Vaz-Da-Silva
LALuis Almeida
Luis Almeida
AFAmílcar Falcão
Amílcar Falcão
PSPedro Silveira
Pedro Silveira
PSPatricio Soares-Da-Silva
Patricio Soares-Da-Silva